Compare AEE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEE | WAT |
|---|---|---|
| Founded | 1901 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 33.5B |
| IPO Year | 1995 | 1996 |
| Metric | AEE | WAT |
|---|---|---|
| Price | $109.86 | $357.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $115.83 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 1.5M | 821.4K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 21.04 | 0.47 |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $8,799,000,000.00 | N/A |
| Revenue This Year | $7.17 | $104.66 |
| Revenue Next Year | $7.07 | $10.40 |
| P/E Ratio | $85.16 | ★ N/A |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $93.50 | $275.05 |
| 52 Week High | $115.59 | $414.15 |
| Indicator | AEE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 52.91 |
| Support Level | $108.57 | $323.66 |
| Resistance Level | $113.10 | $392.00 |
| Average True Range (ATR) | 2.04 | 12.13 |
| MACD | 0.27 | -2.39 |
| Stochastic Oscillator | 76.09 | 40.34 |
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 900,000 natural gas customers across its two service territories.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.